Direct Effects of Type I Interferons on Cells of the Immune System (original) (raw)

Skip Nav Destination

Molecular Pathways| May 01 2011

Sandra Hervas-Stubbs;

Authors Affiliations': 1Division of Gene Therapy and Hepatology, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, 2Medical Oncology Department and Cell Therapy Unit, University Clinic, University of Navarra, and 3Division of Oncology, CIMA, University of Navarra, Pamplona, Spain; 4Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), and 5INSERM, U1016, Paris, France

Search for other works by this author on:

Jose Luis Perez-Gracia;

Authors Affiliations': 1Division of Gene Therapy and Hepatology, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, 2Medical Oncology Department and Cell Therapy Unit, University Clinic, University of Navarra, and 3Division of Oncology, CIMA, University of Navarra, Pamplona, Spain; 4Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), and 5INSERM, U1016, Paris, France

Search for other works by this author on:

Ana Rouzaut;

Authors Affiliations': 1Division of Gene Therapy and Hepatology, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, 2Medical Oncology Department and Cell Therapy Unit, University Clinic, University of Navarra, and 3Division of Oncology, CIMA, University of Navarra, Pamplona, Spain; 4Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), and 5INSERM, U1016, Paris, France

Search for other works by this author on:

Miguel F. Sanmamed;

Authors Affiliations': 1Division of Gene Therapy and Hepatology, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, 2Medical Oncology Department and Cell Therapy Unit, University Clinic, University of Navarra, and 3Division of Oncology, CIMA, University of Navarra, Pamplona, Spain; 4Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), and 5INSERM, U1016, Paris, France

Search for other works by this author on:

Agnes Le Bon;

Authors Affiliations': 1Division of Gene Therapy and Hepatology, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, 2Medical Oncology Department and Cell Therapy Unit, University Clinic, University of Navarra, and 3Division of Oncology, CIMA, University of Navarra, Pamplona, Spain; 4Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), and 5INSERM, U1016, Paris, France

Search for other works by this author on:

Ignacio Melero

Authors Affiliations': 1Division of Gene Therapy and Hepatology, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, 2Medical Oncology Department and Cell Therapy Unit, University Clinic, University of Navarra, and 3Division of Oncology, CIMA, University of Navarra, Pamplona, Spain; 4Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), and 5INSERM, U1016, Paris, France

Corresponding Author: Ignacio Melero, CIMA and Facultad de Medicina Universidad de Navarra, Av. Pio XII, 57, 31008 Pamplona, Spain. Phone: 34-948194700; Fax: 34-948194717; E-mail: imelero@unav.es or mshervas@unav.es

Search for other works by this author on:

Corresponding Author: Ignacio Melero, CIMA and Facultad de Medicina Universidad de Navarra, Av. Pio XII, 57, 31008 Pamplona, Spain. Phone: 34-948194700; Fax: 34-948194717; E-mail: imelero@unav.es or mshervas@unav.es

Received: October 22 2010

Revision Received: January 17 2011

Accepted: January 17 2011

Online ISSN: 1557-3265

Print ISSN: 1078-0432

©2011 American Association for Cancer Research.

2011

Clin Cancer Res (2011) 17 (9): 2619–2627.

Article history

Received:

October 22 2010

Revision Received:

January 17 2011

Accepted:

January 17 2011

• Split-Screen
• Views Icon Views
  • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
  • Peer Review
• Open the PDF for in another window
• Tools Icon Tools
• Search Site
• Article Versions Icon Versions
  • Version of Record May 1 2011
  • Accepted Manuscript March 3 2011

Abstract

Type I interferons (IFN-I) are well-known inducers of tumor cell apoptosis and antiangiogenesis via signaling through a common receptor interferon alpha receptor (IFNAR). IFNAR induces the Janus activated kinase–signal transducer and activation of transcription (JAK-STAT) pathway in most cells, along with other biochemical pathways that may differentially operate, depending on the responding cell subset, and jointly control a large collection of genes. IFNs-I were found to systemically activate natural killer (NK) cell activity. Recently, mouse experiments have shown that IFNs-I directly activate other cells of the immune system, such as antigen-presenting dendritic cells (DC) and CD4 and CD8 T cells. Signaling through the IFNAR in T cells is critical for the acquisition of effector functions. Cross-talk between IFNAR and the pathways turned on by other surface lymphocyte receptors has been described. Importantly, IFNs-I also increase antigen presentation of the tumor cells to be recognized by T lymphocytes. These IFN-driven immunostimulatory pathways offer opportunities to devise combinatorial immunotherapy strategies. Clin Cancer Res; 17(9); 2619–27. ©2011 AACR.

Background

Types of interferon

Interferons (IFN) were discovered in 1957 by Isaacs and Lindenmann as soluble proteins able to inhibit virus replication in cell cultures (1). There are 3 types of IFNs: type I (IFN-I), type II (IFN-II), and type III (IFN-III; refs. 2, 3). IFNs belonging to all IFN classes are very important for fighting viral infection. In humans, IFNs-I include IFN-α subtypes, IFN-β, IFN-ϵ, IFN-κ, and IFN-ω (2). From an immunologic perspective, IFN-α and IFN-β are the main IFN-I subtypes of interest. Both are produced by almost every cell of the body in response to viral infection and share important antiviral properties. The IFN-α family is a multigenic group of highly homologous polypeptides encoded by more than 13 intronless genes in humans. IFN-β, in contrast, exists as a single gene in most species. IFN-γ is the only IFN-II. This cytokine does not have marked structural homology with IFNs-I and binds a different cell-surface receptor (IFNGR), also composed of 2 different subunits (IFNGR1 and IFNGR2; ref. 2). The recently classified IFN-III consists of 3 IFN-λ molecules (IFN-λ1, IFN-λ2, and IFN-λ3) and signals through a receptor complex consisting of interleukin-10 receptor 2 subunit (IL-10R2) and IL-28 receptor alpha subunit (IL-28Rα; ref. 3). It is well established that IFNs induce the expression of hundreds of genes, which mediate various biological responses. Some of these genes are regulated by the 3 classes of IFNs, whereas others are selectively regulated by distinct IFNs.

Although the role of IFN-II and IFN-III is very important in immune responses, IFN-II has not yet shown any clinical activity for human cancer treatment (4), and IFN-III is not currently developed for any indication (3). However, since the discovery of IFNs, the use of IFN-I in therapy has been very widespread. In fact, systemic injections of IFN-I are approved for the treatment of a variety of diseases, which include solid and hematologic malignancies, multiple sclerosis, and, above all, chronic viral hepatitis. In this review, we focus on the role of IFN-I as a direct immunostimulatory agent directly modifying functions of immune system cells and how these functions can be applied to better therapeutic strategies.

IFN-I signaling pathways

All types of IFN-I signal through a unique heterodimeric receptor, interferon alpha receptor (IFNAR), composed of 2 subunits, IFNAR1 and IFNAR2, which are expressed in most tissues (5). IFNAR1 knockout mice have not only confirmed the role this subunit plays in mediating the biological response to IFNs-I, but have also established the pleiotropic role that these IFNs play in regulating the host response to viral infections and in adaptive immunity (6–8).

Receptor occupancy rapidly triggers several signaling cascades (Fig. 1), which culminate in the transcriptional regulation of hundreds of IFN-stimulated genes (ISG). The first signaling pathway shown to be activated by IFNs-I was the Janus activated kinase–signal transducer and activation of transcription (JAK-STAT) pathway (Fig. 1A; ref. 9), which is active in almost all cell types. IFNAR1 is constitutively associated with tyrosine kinase 2 (TYK2), whereas IFNAR2 is associated with JAK1. Receptor binding results in transphosphorylation of JAK1 and TYK2. The activated JAKs then phosphorylate conserved tyrosine residues in the cytoplasmic tails of the IFNAR. These phosphotyrosyl residues subsequently serve as docking sites for the recruitment of src-homology 2 (SH2)–containing signaling molecules, such as STAT1 and STAT2. Once at the receptor, the STAT proteins themselves become JAK substrates. STAT1 and STAT2 are both phosphorylated on a single tyrosine (Y701 for STAT1 and Y690 for STAT2). Once phosphorylated, STATs dimerize and move to the nucleus, where they associate with the IFN-regulatory factor 9 (IRF9) to form the ISG factor 3 (ISGF3) transcription factor complex, which binds to IFN-stimulated response elements.

Figure 1.

Signaling pathways activated by the IFN-I receptor. Schematic of signaling pathways downstream of the IFNAR, emphasizing cross-talk with different signaling cascades, which depends on the identity and activation status of the cell responding to IFN-I. A, JAK-STAT signal pathway activated by IFNs-I. B, CRKL pathway. Upon JAK activation, CRKL associates with TYK2 and undergoes tyrosine phosphorylation. The activated form of CRKL forms a complex with STAT5, which also undergoes TYK2-dependent tyrosine phosphorylation. The CRKL–STAT5 complex translocates to the nucleus and binds specific GAS elements. C, PI3K and NF-κB pathways. Phosphorylation of TYK2 and JAK1 results in activation of PI3K and AKT, which in turn mediates downstream activation of mTOR, inactivation of GSK-3, CDKN1A, and CDKN1B, and activation of IKKβ, which results in activation of NF-κB. IFNs-I also activate NF-κB by an alternative pathway that involves the linkage of TRAFs, which results in activation of NF-κB2. PI3K/AKT can also activate NF-κB through an activation loop via PKCθ. D, MAPK pathway. Activation of JAK results in tyrosine phosphorylation of Vav, which leads to the activation of several MAPKs such as p38, JNK, and ERK1/2. The different MAPKs activate different sets of transcription factors, such as Fos, ELK1, Sap-1, MEF2, MAPKAP, and Rsk (activated by p38); Jun, ELK1, NFAT, and ATF2 (activated by JNK); and NFAT, ETS, ELK1, MEF2, STAT1/2, c-Myc, SAP-1, p53, SP1, and SMADs (activated by ERK1/2).

Figure 1.

Signaling pathways activated by the IFN-I receptor. Schematic of signaling pathways downstream of the IFNAR, emphasizing cross-talk with different signaling cascades, which depends on the identity and activation status of the cell responding to IFN-I. A, JAK-STAT signal pathway activated by IFNs-I. B, CRKL pathway. Upon JAK activation, CRKL associates with TYK2 and undergoes tyrosine phosphorylation. The activated form of CRKL forms a complex with STAT5, which also undergoes TYK2-dependent tyrosine phosphorylation. The CRKL–STAT5 complex translocates to the nucleus and binds specific GAS elements. C, PI3K and NF-κB pathways. Phosphorylation of TYK2 and JAK1 results in activation of PI3K and AKT, which in turn mediates downstream activation of mTOR, inactivation of GSK-3, CDKN1A, and CDKN1B, and activation of IKKβ, which results in activation of NF-κB. IFNs-I also activate NF-κB by an alternative pathway that involves the linkage of TRAFs, which results in activation of NF-κB2. PI3K/AKT can also activate NF-κB through an activation loop via PKCθ. D, MAPK pathway. Activation of JAK results in tyrosine phosphorylation of Vav, which leads to the activation of several MAPKs such as p38, JNK, and ERK1/2. The different MAPKs activate different sets of transcription factors, such as Fos, ELK1, Sap-1, MEF2, MAPKAP, and Rsk (activated by p38); Jun, ELK1, NFAT, and ATF2 (activated by JNK); and NFAT, ETS, ELK1, MEF2, STAT1/2, c-Myc, SAP-1, p53, SP1, and SMADs (activated by ERK1/2).

Close modal

Although STAT1 and STAT2 are the most important mediators of the response to IFNs-I, other STATs, namely STAT3 and STAT5, have been found to be phosphorylated (activated) by IFNs-I (Fig. 1A; refs. 10–13). STAT4 and STAT6 can also be activated by IFN-α; however, this activation seems to be restricted to certain cell types, such as endothelial or lymphoid cells (14–17). Following phosphorylation, activated STATs form homo- (STAT1, STAT3, STAT4, STAT5, and STAT6) or heterodimers (STAT1/2, STAT1/3, STAT1/4, STAT1/5, STAT2/3, and STAT5/6; refs. 10, 11, 18, 19), which translocate to the nucleus and bind other regulatory sequences known as IFN-γ–activated sites (GAS).

Interestingly, distinct STATs have opposing biological effects. Thus, STAT3 stimulates growth, whereas on the contrary, STAT1 is a growth inhibitor. On the other hand, IFNs-I–mediated activation of STAT4 is required for IFN-γ production, whereas surprisingly, STAT1 negatively regulates the IFNs-I–dependent induction of IFN-γ (20). The relative abundance of these dimeric transcription factors, which may vary substantially depending on cell type and activation and/or differentiation state, is likely to have a major impact on the overall response to IFNs-I (21–23).

Stimulation of the IFNAR/JAK/STAT1 pathway can also lead to the upregulation of the TAM receptor Axl, which accumulates at the cell surface where it physically associates with the IFNAR and usurps the IFNAR-STAT1 pathway by stimulating the transcription of suppressors of cytokine signaling (SOCS; refs. 24, 25). The SOCS proteins extinguish IFN-I signaling in a negative feedback loop. For instance, SOCS1 directly interacts with JAKs blocking their catalytic activity, whereas SOCS3 seems to inhibit JAKs after gaining access by receptor binding. In addition, SOCS proteins interact with the cellular ubiquitination machinery through the SOCS-box region and may redirect associated proteins, such as JAKs or IFNAR chains, to proteasomal degradation. It has been shown that SOCS1 knockout mice develop lupus-like disease symptoms (26) and that SOCS1 silencing enhances the antitumor activity of IFNs-I (27), suggesting that SOCS are key elements in keeping IFNs-I effects under control.

Alternative signaling pathways and cross-talk with other receptors

Evidence is accumulating that several other signaling elements and cascades are required for the generation of many of the responses to IFNs-I, such as the v-crk sarcoma virus CT10 oncogene homolog (avian)-like (CRKL) pathway, the mitogen activated protein kinase (MAPK) pathway, the phosphoinositide 3-kinase (PI3K) pathway, and either the classical or the alternative NF-κB cascade (Fig. 1B-D; refs. 9, 28). Some of these pathways operate independently of the JAK-STAT, whereas others cooperate with STATs to tune the response to IFNs-I. Interestingly, MAPK, PI3K, and NF-κB pathways involve immunoreceptor tyrosine-based activation motives used by classical immunoreceptors, suggesting a cross-talk among IFNAR and multiple receptors on immune system cells.

The PI3K and NF-κB pathways.

Upon activation, TYK2 and JAK1 phosphorylate insulin receptor substrate 1 (IRS1) and 2 (IRS2), which provide docking sites for the PI3K (9). STAT3 acts as an adapter to couple PI3K to the IFNAR1 subunit. PI3K subsequently activates the serine-threonine kinase AKT, which in turn mediates downstream the activation of mTOR and the inactivation of several proteins, such as glycogen synthase kinase 3 (GSK-3) and cyclin dependent kinase inhibitors 1A and 1B (CDKN1A and CDKN1B), all of them involved in the control of cell division and proliferation. The AKT pathway also results in the activation of IκB kinase beta (IKKβ), which gives rise to NF-κB activation. IFNs-I also activate NF-κB by an alternative pathway, which involves the linkage of TNF receptor–associated factors (TRAF) to the activation of the NF-κB–inducing kinase (NIK), which in turn results in activation of NF-κB2. This alternative pathway is strictly dependent on the activity of IKKα. In addition, PI3K/AKT can also activate NF-κB through an activation loop via protein kinase C zeta (PKCθ). Overall, NF-κB activated by IFNs-I regulates prosurvival signals and enhances the expression of several GTP-binding proteins as well as molecules involved in antigen processing and/or presentation.

The MAPK pathway.

Activation of JAK results in tyrosine phosphorylation of the guanine nucleotide exchange factor Vav, which leads to downstream activation of Rat sarcoma protein (Ras) and ras-related C3 botulinum toxin substrate 1 (Rac1), which subsequently leads to the activation of several MAPKs: p38, c-Jun _N_-terminal kinases (JNK), and extracellular signal regulated kinases (ERK) 1 and 2 (9). Vav can also activate PKCθ, leading to the activation of the NF-κB cascade. Several studies have shown that IFN-α–mediated activation of ERK1/2 in T lymphocytes requires proteins involved in the T-cell receptor (TCR) early signaling complex, such as CD45, lymphocyte-specific protein tyrosine kinase (Lck), Zeta-chain-associated protein kinase 70 (Zap70), SH2 domain-containing leukocyte protein of 76 kDa (SLP76), and Vav1, and possibly linker for activation of T cells (LAT), indicating cross-talk between pathways (29–31). Moreover, it has been shown recently that TCR deletion in Jurkat cells abrogated IFNAR-stimulated MAPK activity, whereas the canonical JAK-STAT pathway remained unaffected (31). A hypothetical pathway that involves all these molecules and results in Vav activation is depicted in Fig. 1D. The different MAPKs activate different sets of transcription factors. Importantly, p38 functions are essential for the antiviral and antileukemic properties of IFNs-I, it plays a role in the hematopoietic-suppressive signals and is required for the growth-inhibitory effects of IFNs-I observed in certain lymphocyte cultures. IFNs-I–activated ERK cascades regulate cellular growth, differentiation, and serine phosphorylation of STAT1. The search for biochemical signals to explain the effects of IFN-I on immune system cells is far from over.

Effects of IFNs-I on cells of the immune system

It has long been established that the main mechanism accounting for the efficacy of the IFN-I–based therapies was due to their direct effect on malignant or virus-infected cells. In fact, IFNs-I directly inhibit the proliferation of tumor and virus-infected cells and increase MHC class I expression, enhancing antigen recognition. Moreover, IFNs-I repress oncogene expression and induce that of tumor suppressor genes, which may contribute to the inhibitory effects of IFN-I on malignant cells in conjunction with the antiangiogenic effects.

IFNs-I have also proven to be involved in immune system regulation (7, 8, 32). IFNs-I exert their effects on immune cells either directly, through IFNAR triggering, or indirectly (i) by the induction of chemokines, which allow the recruitment of immune cells to the site of infection; (ii) by the secretion of a second wave of cytokines, which could further regulate cell numbers and activities (as for example IL-15, which plays a critical role in proliferation and maintenance of NK cells and memory CD8 T cells; refs. 33, 34); or (iii) by the stimulation of other cell types critical for the activation of certain immune cells, such as DC for the activation of naïve T cells.

One of the earliest described immunoregulatory functions of IFNs-I was their ability to regulate NK functions (32). IFNs-I enhance the ability of NK cells to kill target cells and to produce IFN-γ by indirect and direct mechanisms (33, 35, 36). Furthermore, IFNs-I promote the accumulation and/or survival of proliferating NK cells by the IFN-I/STAT1–dependent induction of IL-15 (33). IFNs-I also enhance the production or secretion of other cytokines by the NK cell through the autocrine IFN-γ loop (37).

IFNs-I also affect monocyte and/or macrophage function and differentiation. Thus, IFNs-I markedly support the differentiation of monocytes into DC with high capacity for Ag presentation, stimulate macrophage antibody-dependent cytotoxicity, and positively or negatively regulate the production of various cytokines (e.g., TNF, IL-1, IL-6, IL-8, IL-12, and IL-18) by macrophages (38). In addition, autocrine IFN-I is required for the enhancement of macrophage phagocytosis by macrophage colony-stimulating factor and IL-4 (39) and for the lipopolysaccharide-, virus-, and IFN-γ–induced oxidative burst through the generation of nitric oxide synthase 2.

The main function of DCs is to uptake and process antigens for presentation to T cells. DCs are a unique cell type able to prime naïve T cells and, therefore, are critical antigen presenting cells (APC). IFNs-I have multiple effects on DCs, affecting their differentiation, maturation, and migration. Thus, human monocytes cultured in granulocyte-macrophage colony-stimulating factor (GM-CSF) + IFN-α/β, rather than the more commonly used combination of GM-CSF + IL-4, differentiate more rapidly into DCs, exhibiting the phenotype of partially mature DCs, while showing a strong capability to induce a primary human antibody response and CTL expansion when pulsed with antigen and injected into humanized severe combined immunodeficiency (SCID) mice (40–42).

In vitro treatment of immature conventional DCs with IFN-α/β has been shown to upregulate surface expression of MHC class I, class II, CD40, CD80, CD86, and CD83 molecules in the human system (43–45), associated with a heightened capacity to induce CD8 T-cell responses. Accordingly, it has been observed in mice that IFN-α acting on DC plays a key role in achieving efficient cross-priming of antigen-specific CD8 T lymphocytes (7, 8, 32). IFNs-I also affect the ability of DC to secrete IL-12p70. Low concentrations of IFNs-I are essential for the optimal production of IL-12p70 (46), whereas higher levels of IFN-I suppress IL-12p40 expression, thus dampening IL-12p70 production (47).

A key requisite to initiate the adaptive immune response is the arrival of professional APC from infected tissue into lymph nodes. It has been shown that human DCs differentiated from monocytes in the presence of IFN-α exhibit upregulation of CC chemokine receptor type 7 (CCR7), correlating with an enhanced chemotactic response in vitro to CCR7 natural ligand (CCL19) and with strong migratory behavior in SCID mice (48). Interestingly, experiments in mice have also shown that IFN-α/β is required for plasmacytoid DCs (pDC) to migrate from the marginal zone into the T-cell area, where they form clusters (49). We have also recently shown that IFNs-I enhance the adhesion and extravasations of DCs across inflamed lymphatic endothelium in a lymphocyte function-associated antigen 1 (LFA-1)– and very late antigen-4 (VLA4)–dependent fashion (50). IFNs-I may also favor the encounter between DCs and specific lymphocytes in lymph nodes by promoting lymphocyte trapping in lymph nodes upon downmodulation of sphingosine 1-phosphate (51).

IFNs-I have also been shown to potently enhance the primary antibody response to soluble antigen, stimulating the production of all subtypes of immunoglobulin G (IgG), and inducing long-lived antibody production and immunologic memory (8). Direct effects of IFN-α on DCs (8), B cells (52, 53), and CD4 T cells (53) all contribute to its adjuvant activities on humoral immune responses. Interestingly, a direct effect of IFNs-I on B cells seems to be crucial for the development of local humoral responses against viruses (54).

As mentioned above, CD4 T cells are direct targets of IFN-I in the enhancement of antibody responses (53). In humans, it has also been described that direct effects of IFN-I on naive CD4 T cells favor their differentiation into IFN-γ–secreting Th1-like T cells (55).

Several studies suggested that IFNs-I might exert a direct effect on CD8 T cells. Thus, it was reported that IFNs-I promote IFN-γ production by CD8 T cells in a STAT4-dependent manner (56) and promote survival of CD8 T cells from wild-type (WT) but not IFNAR-deficient (IFNAR−/−) mice (57). The definitive report showing that CD8 T cells represent direct targets of IFN-I–mediated stimulation in vivo came from Kolumam and colleagues (58). By adoptively transferring virus-specific naive CD8 T cells from IFNAR−/− or IFNAR-sufficient mice into normal IFNAR WT hosts, IFNs-I were shown to act directly on murine CD8 T cells, allowing their clonal expansion and memory differentiation. Subsequent studies confirmed this work (59–61). Elegant experiments in mice by Curtsinger and colleagues (62) have shown that, in addition to signals via TCR (signal-1) and CD28 (signal-2), naïve CD8 T cells required a third signal to differentiate into effector cells. cDNA microarray analyses showed that IFN-α could regulate critical genes involved in CTL functions (63), providing evidence that IFNα promoted activation and differentiation of CD8 T cells by sustaining the expression of T-bet and Eomes through chromatin remodeling. Recently, we have shown that IFN-α provides a strong and direct signal to human CD8 T cells, thereby resulting in upregulation of critical genes for cytotoxic T-cell activity (cytolysis and IFN-γ secretion) and for the production of chemokines that would coattract other effector lymphocytes. IFN-α was absolutely critical in the case of human naïve CD8 T cells for effector function acquisition (64). In many instances, T cells may sense IFN-I before the cognate antigen is actually presented to them. As a result of a preexposure to IFN-I, CD8 T cells become preactivated and acquire much faster effector functions upon antigen recognition (65). This preactivation may reflect the upregulation by IFN-I of several mRNAs in antigen-naive CD8 T lymphocyte, albeit without changes in the expression of the corresponding protein, unless antigen-specific activation ensues (64).

Clinical-Translational Advances

The contracting current indications of IFN-α as an anticancer agent

IFN-α has received approval for treatment of several neoplastic diseases (66). The most frequent indications for IFN-α are chronic viral hepatitis. For the treatment of these infectious conditions, stabilized forms of IFN-α have been created by directed conjugation of polyethylene glycol, which, by increasing molecular weight, retards renal clearance and, thereby, extends plasma concentrations with sustained receptor occupancy (67). However, PEG-conjugated IFN is not widely used in oncology in the absence of comparative clinical studies with the unconjugated form.

In oncology, the main indication of IFN-α is for patients with resected stage II and III melanoma, in whom IFN-α prolongs disease-free survival and shows a trend toward increased overall survival (68). However, the advent of CTLA-4 antagonist antibodies will very likely displace the use of IFN-α for melanoma therapy (69).

Table 1 shows the spectrum of neoplastic diseases in which IFN-α has been used. As shown, its role in cancer therapy is steadily decreasing because of its limited efficacy and the advent of new, more effective, and/or safer treatments.

Table 1.

Contracting Indications of IFN-α for Malignant Conditions

PV, polycythemia vera; ET, essential thrombocythemia; PM, primary myelofibrosis; RCC, renal cell cancer; CMS, chronic myeloproliferative syndrome; CML, chronic myeloid leukemia

Future perspectives

IFNs-I are powerful tools to directly and indirectly modulate the functions of the immune system. Evolution has shaped these cytokines as a key sign of alarm in case of viral infection. The type of immune response that we would like to induce and sustain against cancer antigens is identical to the one we commonly observe upon acute viral infections. Obviously, the effects of IFN-I are integrated with many other key molecules that need to act in a concerted fashion.

As described in Table 1, side effects of systemic long-term treatments and lack of sufficiently high efficacy have dampened the interest of IFN-α for clinical use in oncology. However, we believe that IFN-α is likely to be more efficacious when acting locally and intermittently at the malignant tissue and tumor-draining lymph node than when administered to achieve systemic bioavailability. Local delivery can be achieved with pharmaceutical formulations and gene therapy approaches (70). In our opinion, the clinical use of recombinant IFN-α as a vaccine adjuvant should be reconsidered and new investigations carried out with an eye to clinical applications (71).

The rationale for using intermittent delivery arises from observations indicating that IFN-I turns on signaling desensitizing mechanisms (i.e., because of SOCS1 induction). Intermittency at an optimized pace may help to avoid these negative feedback mechanisms in the responding immune cells. These ideas contrast with stabilized formulations, such as the widely used polyethylene glycol-conjugated IFN-α and fusion proteins with albumin that extend the half-life of the cytokine.

It is of much interest that a gene expression signature induced by IFN-I in melanoma lesions predicts benefit from vaccines and may have a key role in recruiting effector T cells to tumors by inducing chemokine genes (72). IFN-α has been recently used in promising combinatorial immunotherapy approaches alongside DC vaccination for glioblastoma, precisely to promote T-cell infiltration and DC activation (73). In this regard, using endogenous IFN-I inducers instead of recombinant cytokines may have advantages, because substances such as the viral RNA analog poly I:C will also elicit other cytokines that may act in concert with IFNs-I to enhance the antitumor immune response.

Creative combination strategies are building on the knowledge that IFN-α effects on the immune system are likely to improve its therapeutic profile against malignant diseases. For instance, combinations with immunostimulatory monoclonal antibodies, IL-15, IL-12, and IL-21, may hold much promise. Indeed, intratumoral release of mouse IFN-α along with systemic treatment with anti-CD137 mAb results in synergistic therapeutic effects (74). Macrophages homing to tumor, transduced to express IFN-α, exert therapeutic effects without the systemic side effects (75). These studies suggest that local delivery as opposed to systemic administration should be tested. Of great importance is the notion that the chemokines induced by IFN-I (i.e., CXCL9, CXCL10) attract activated lymphocytes, thereby calling more immune cells to infiltrate the malignant focus.

When reflecting on the use of IFN-I for cancer, we must think about reprogramming the tumor microenvironment, frequently devoid of any stimulatory signals. Local IFN-I release with concomitant irradiation and chemotherapy may help to turn some of the macroscopic tumor lesions into immunogenic vaccines. Factors such as CpG oligonucleotides or poly I:C that induce the release of endogenous IFNs-I at a given tumor lesion (76) are promising in this regard. These agents may constitute an advantageous alternative because these agents also induce an additional array of proinflammatory mediators acting in synergy with IFNs-I.

In conclusion, the notion of key direct effects of IFNs-I on immune system cells and detailed knowledge on the elicited signaling pathways should help biomarker discovery to identify the small number of patients who could actually benefit from current treatments. More importantly, these ideas might change the way we use IFN-α for cancer therapy, suggesting new strategies and combinations with other agents.

Disclosure of Potential Conflicts of Interest

I. Melero, A. Rouzaut, and S. Hervas-Stubbs receive laboratory reagents and research funding from Digna Biotech. I. Melero has acted as a consultant for Bristol-Myers Squibb and Pfizer Inc.

Acknowledgments

We are grateful for continuous scientific collaboration on IFNs-I with Jesús Prieto, Esther Larrea, Jose I. Riezu-Boj, Iranzu Gonzalez, and Juan Ruiz.

Grant Support

MEC/MCI (SAF2005–03131, SAF2008–03294, and TRA2009–0030), Departamento de Educación y Departamento de Salud (Beca Ortiz de Landázuri) del Gobierno de Navarra. Redes temáticas de investigación cooperativa RETIC (RD06/0020/0065), Fondo de investigación sanitaria (FIS PI060932), European commission VII framework program (ENCITE), Immunonet SUDOE. Fundación Mutua Madrileña, and “UTE for project FIMA”. S. Hervas-Stubbs was supported by AECC and by MCI (RYC-2007–00928).

References

Isaacs

A

,

Lindenmann

J

.

Virus interference. I. The interferon

.

Proc R Soc Lond B Biol Sci

1957

;

147

:

258

–

67

.

Pestka

S

,

Krause

CD

,

Walter

MR

.

Interferons, interferon-like cytokines, and their receptors

.

Immunol Rev

2004

;

202

:

8

–

32

.

Vilcek

J

.

Novel interferons

.

Nat Immunol

2003

;

4

:

8

–

9

.

Miller

CH

,

Maher

SG

,

Young

HA

.

Clinical Use of Interferon-gamma

.

Ann N Y Acad Sci

2009

;

1182

:

69

–

79

.

de Weerd

NA

,

Samarajiwa

SA

,

Hertzog

PJ

.

Type I interferon receptors: biochemistry and biological functions

.

J Biol Chem

2007

;

282

:

20053

–

7

.

Hwang

SY

,

Hertzog

PJ

,

Holland

KA

,

Sumarsono

SH

,

Tymms

MJ

,

Hamilton

JA

, et al

A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses

.

Proc Natl Acad Sci U S A

1995

;

92

:

11284

–

8

.

Le Bon

A

,

Etchart

N

,

Rossmann

C

,

Ashton

M

,

Hou

S

,

Gewert

D

, et al

Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

.

Nat Immunol

2003

;

4

:

1009

–

15

.

Le Bon

A

,

Schiavoni

G

,

D'Agostino

G

,

Gresser

I

,

Belardelli

F

,

Tough

DF

.

Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo

.

Immunity

2001

;

14

:

461

–

70

.

Platanias

LC

.

Mechanisms of type-I- and type-II-interferon-mediated signalling

.

Nat Rev Immunol

2005

;

5

:

375

–

86

.

Aaronson

DS

,

Horvath

CM

.

A road map for those who don't know JAK-STAT

.

Science

2002

;

296

:

1653

–

5

.

Darnell

JE

Jr.

STATs and gene regulation

.

Science

1997

;

277

:

1630

–

5

.

Darnell

JE

Jr,

Kerr

IM

,

Stark

GR

.

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

.

Science

1994

;

264

:

1415

–

21

.

Meinke

A

,

Barahmand-Pour

F

,

Wöhrl

S

,

Stoiber

D

,

Decker

T

.

Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons

.

Mol Cell Biol

1996

;

16

:

6937

–

44

.

Farrar

JD

,

Smith

JD

,

Murphy

TL

,

Murphy

KM

.

Recruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2

.

J Biol Chem

2000

;

275

:

2693

–

7

.

Fasler-Kan

E

,

Pansky

A

,

Wiederkehr

M

,

Battegay

M

,

Heim

MH

.

Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells

.

Eur J Biochem

1998

;

254

:

514

–

9

.

Matikainen

S

,

Sareneva

T

,

Ronni

T

,

Lehtonen

A

,

Koskinen

PJ

,

Julkunen

I

.

Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells

.

Blood

1999

;

93

:

1980

–

91

.

Torpey

N

,

Maher

SE

,

Bothwell

AL

,

Pober

JS

.

Interferon alpha but not interleukin 12 activates STAT4 signaling in human vascular endothelial cells

.

J Biol Chem

2004

;

279

:

26789

–

96

.

Parmar

S

,

Platanias

LC

.

Interferons: mechanisms of action and clinical applications

.

Curr Opin Oncol

2003

;

15

:

431

–

9

.

Platanias

LC

,

Fish

EN

.

Signaling pathways activated by interferons

.

Exp Hematol

1999

;

27

:

1583

–

92

.

Nguyen

KB

,

Cousens

LP

,

Doughty

LA

,

Pien

GC

,

Durbin

JE

,

Biron

CA

.

Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox

.

Nat Immunol

2000

;

1

:

70

–

6

.

Levy

DE

,

Lee

CK

.

What does Stat3 do?

J Clin Invest

2002

;

109

:

1143

–

8

.

Qing

Y

,

Stark

GR

.

Alternative activation of STAT1 and STAT3 in response to interferon-gamma

.

J Biol Chem

2004

;

279

:

41679

–

85

.

Ramana

CV

,

Kumar

A

,

Enelow

R

.

Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts

.

Biochem Biophys Res Commun

2005

;

327

:

727

–

33

.

Alexander

WS

.

Suppressors of cytokine signalling (SOCS) in the immune system

.

Nat Rev Immunol

2002

;

2

:

410

–

6

.

Yoshimura

A

,

Naka

T

,

Kubo

M

.

SOCS proteins, cytokine signalling and immune regulation

.

Nat Rev Immunol

2007

;

7

:

454

–

65

.

Hanada

T

,

Yoshida

H

,

Kato

S

,

Tanaka

K

,

Masutani

K

,

Tsukada

J

, et al

Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity

.

Immunity

2003

;

19

:

437

–

50

.

Zitzmann

K

,

Brand

S

,

De Toni

EN

,

Baehs

S

,

Göke

B

,

Meinecke

J

, et al

SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells

.

Cancer Res

2007

;

67

:

5025

–

32

.

Du

Z

,

Wei

L

,

Murti

A

,

Pfeffer

SR

,

Fan

M

,

Yang

CH

, et al

Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway

.

J Cell Biochem

2007

;

102

:

1087

–

94

.

Ahmed

Z

,

Beeton

CA

,

Williams

MA

,

Clements

D

,

Baldari

CT

,

Ladbury

JE

.

Distinct spatial and temporal distribution of ZAP70 and Lck following stimulation of interferon and T-cell receptors

.

J Mol Biol

2005

;

353

:

1001

–

10

.

Petricoin

EF

3rd,

Ito

S

,

Williams

BL

,

Audet

S

,

Stancato

LF

,

Gamero

A

, et al

Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling

.

Nature

1997

;

390

:

629

–

32

.

Stevens

CN

,

Simeone

AM

,

John

S

,

Ahmed

Z

,

Lucherini

OM

,

Baldari

CT

, et al

T-cell receptor early signalling complex activation in response to interferon-alpha receptor stimulation

.

Biochem J

2010

;

428

:

429

–

37

.

Trinchieri

G

,

Santoli

D

.

Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis

.

J Exp Med

1978

;

147

:

1314

–

33

.

Nguyen

KB

,

Salazar-Mather

TP

,

Dalod

MY

,

Van Deusen

JB

,

Wei

XQ

,

Liew

FY

, et al

Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection

.

J Immunol

2002

;

169

:

4279

–

87

.

Zhang

X

,

Sun

S

,

Hwang

I

,

Tough

DF

,

Sprent

J

.

Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15

.

Immunity

1998

;

8

:

591

–

9

.

Lee

CK

,

Rao

DT

,

Gertner

R

,

Gimeno

R

,

Frey

AB

,

Levy

DE

.

Distinct requirements for IFNs and STAT1 in NK cell function

.

J Immunol

2000

;

165

:

3571

–

7

.

Trinchieri

G

,

Santoli

D

,

Granato

D

,

Perussia

B

.

Antagonistic effects of interferons on the cytotoxicity mediated by natural killer cells

.

Fed Proc

1981

;

40

:

2705

–

10

.

Ortaldo

JR

,

Phillips

W

,

Wasserman

K

,

Herberman

RB

.

Effects of metabolic inhibitors on spontaneous and interferon-boosted human natural killer cell activity

.

J Immunol

1980

;

125

:

1839

–

44

.

Bogdan

C

,

Mattner

J

,

Schleicher

U

.

The role of type I interferons in non-viral infections

.

Immunol Rev

2004

;

202

:

33

–

48

.

Sampson

LL

,

Heuser

J

,

Brown

EJ

.

Cytokine regulation of complement receptor-mediated ingestion by mouse peritoneal macrophages. M-CSF and IL-4 activate phagocytosis by a common mechanism requiring autostimulation by IFN-beta

.

J Immunol

1991

;

146

:

1005

–

13

.

Lapenta

C

,

Santini

SM

,

Logozzi

M

,

Spada

M

,

Andreotti

M

,

Di Pucchio

T

, et al

Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha

.

J Exp Med

2003

;

198

:

361

–

7

.

Santini

SM

,

Lapenta

C

,

Logozzi

M

,

Parlato

S

,

Spada

M

,

Di Pucchio

T

, et al

Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice

.

J Exp Med

2000

;

191

:

1777

–

88

.

Santodonato

L

,

D'Agostino

G

,

Nisini

R

,

Mariotti

S

,

Monque

DM

,

Spada

M

, et al

Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response

.

J Immunol

2003

;

170

:

5195

–

202

.

Gallucci

S

,

Lolkema

M

,

Matzinger

P

.

Natural adjuvants: endogenous activators of dendritic cells

.

Nat Med

1999

;

5

:

1249

–

55

.

Ito

T

,

Amakawa

R

,

Inaba

M

,

Ikehara

S

,

Inaba

K

,

Fukuhara

S

.

Differential regulation of human blood dendritic cell subsets by IFNs

.

J Immunol

2001

;

166

:

2961

–

9

.

Montoya

M

,

Schiavoni

G

,

Mattei

F

,

Gresser

I

,

Belardelli

F

,

Borrow

P

, et al

Type I interferons produced by dendritic cells promote their phenotypic and functional activation

.

Blood

2002

;

99

:

3263

–

71

.

Gautier

G

,

Humbert

M

,

Deauvieau

F

,

Scuiller

M

,

Hiscott

J

,

Bates

EE

, et al

A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells

.

J Exp Med

2005

;

201

:

1435

–

46

.

Byrnes

AA

,

Ma

X

,

Cuomo

P

,

Park

K

,

Wahl

L

,

Wolf

SF

, et al

Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity

.

Eur J Immunol

2001

;

31

:

2026

–

34

.

Parlato

S

,

Santini

SM

,

Lapenta

C

,

Di Pucchio

T

,

Logozzi

M

,

Spada

M

, et al

Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities

.

Blood

2001

;

98

:

3022

–

9

.

Asselin-Paturel

C

,

Boonstra

A

,

Dalod

M

,

Durand

I

,

Yessaad

N

,

Dezutter-Dambuyant

C

, et al

Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology

.

Nat Immunol

2001

;

2

:

1144

–

50

.

Rouzaut

A

,

Garasa

S

,

Teijeira

A

,

Gonzalez

I

,

Martinez-Forero

I

,

Larrea

E

, et al

Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-a

.

Eur J Immunol

2010

;

40

:

3054

–

63

.

Shiow

LR

,

Rosen

DB

,

Brdicková

N

,

Xu

Y

,

An

J

,

Lanier

LL

, et al

CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs

.

Nature

2006

;

440

:

540

–

4

.

Fink

K

,

Lang

KS

,

Manjarrez-Orduno

N

,

Junt

T

,

Senn

BM

,

Holdener

M

, et al

Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses

.

Eur J Immunol

2006

;

36

:

2094

–

105

.

Le Bon

A

,

Thompson

C

,

Kamphuis

E

,

Durand

V

,

Rossmann

C

,

Kalinke

U

, et al

Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN

.

J Immunol

2006

;

176

:

2074

–

8

.

Coro

ES

,

Chang

WL

,

Baumgarth

N

.

Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection

.

J Immunol

2006

;

176

:

4343

–

51

.

Brinkmann

V

,

Geiger

T

,

Alkan

S

,

Heusser

CH

.

Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells

.

J Exp Med

1993

;

178

:

1655

–

63

.

Nguyen

KB

,

Watford

WT

,

Salomon

R

,

Hofmann

SR

,

Pien

GC

,

Morinobu

A

, et al

Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection

.

Science

2002

;

297

:

2063

–

6

.

Marrack

P

,

Kappler

J

,

Mitchell

T

.

Type I interferons keep activated T cells alive

.

J Exp Med

1999

;

189

:

521

–

30

.

Kolumam

GA

,

Thomas

S

,

Thompson

LJ

,

Sprent

J

,

Murali-Krishna

K

.

Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection

.

J Exp Med

2005

;

202

:

637

–

50

.

Aichele

P

,

Unsoeld

H

,

Koschella

M

,

Schweier

O

,

Kalinke

U

,

Vucikuja

S

.

CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion

.

J Immunol

2006

;

176

:

4525

–

9

.

Le Bon

A

,

Durand

V

,

Kamphuis

E

,

Thompson

C

,

Bulfone-Paus

S

,

Rossmann

C

, et al

Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming

.

J Immunol

2006

;

176

:

4682

–

9

.

Thompson

LJ

,

Kolumam

GA

,

Thomas

S

,

Murali-Krishna

K

.

Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation

.

J Immunol

2006

;

177

:

1746

–

54

.

Curtsinger

JM

,

Valenzuela

JO

,

Agarwal

P

,

Lins

D

,

Mescher

MF

,

Type

I

.

Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation

.

J Immunol

2005

;

174

:

4465

–

9

.

Agarwal

P

,

Raghavan

A

,

Nandiwada

SL

,

Curtsinger

JM

,

Bohjanen

PR

,

Mueller

DL

, et al

Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory

.

J Immunol

2009

;

183

:

1695

–

704

.

Hervas-Stubbs

S

,

Riezu-Boj

J-I

,

Gonzalez

I

,

Mancheno

U

,

Dubrot

J

,

Azpilicueta

A

, et al

Effects of IFNa as a signal-3 cytokine on human naïve and antigen-experienced CD8 T-cells

.

Eur J Immunol

2010

;

40

:

3389

–

402

.

Marshall

HD

,

Prince

AL

,

Berg

LJ

,

Welsh

RM

.

IFN-alpha beta and self-MHC divert CD8 T cells into a distinct differentiation pathway characterized by rapid acquisition of effector functions

.

J Immunol

2010

;

185

:

1419

–

28

.

Kirkwood

J

.

Cancer immunotherapy: the interferon-alpha experience

.

Semin Oncol

2002

;

29

:

18

–

26

.

Wedemeyer

H

,

Wiegand

J

,

Cornberg

M

,

Manns

MP

.

Polyethylene glycol-interferon: current status in hepatitis C virus therapy

.

J Gastroenterol Hepatol

2002

;

17

[Suppl 3]

:

S344

–

50

.

Garbe

C

,

Eigentler

TK

.

Diagnosis and treatment of cutaneous melanoma: state of the art 2006

.

Melanoma Res

2007

;

17

:

117

–

27

.

Hanley

PJ

,

Cruz

CR

,

Savoldo

B

,

Leen

AM

,

Stanojevic

M

,

Khalil

M

, et al

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes

.

Blood

2009

;

114

:

1958

–

67

.

Sterman

DH

,

Recio

A

,

Haas

AR

,

Vachani

A

,

Katz

SI

,

Gillespie

CT

, et al

A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions

.

Mol Ther

2010

;

18

:

852

–

60

.

Bracci

L

,

La Sorsa

V

,

Belardelli

F

,

Proietti

E

.

Type I interferons as vaccine adjuvants against infectious diseases and cancer

.

Expert Rev Vaccines

2008

;

7

:

373

–

81

.

Harlin

H

,

Meng

Y

,

Peterson

AC

,

Zha

Y

,

Tretiakova

M

,

Slingluff

C

, et al

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

.

Cancer Res

2009

;

69

:

3077

–

85

.

Okada

H

,

Kalinski

P

,

Ueda

R

,

Hoji

A

,

Kohanbash

G

,

Donegan

TE

, et al

Induction of CD8 T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma

.

J Clin Oncol

2011

;

29

:

330

–

6

.

Dubrot

J

,

Palazón

A

,

Alfaro

C

,

Azpilikueta

A

,

Ochoa

MC

,

Rouzaut

A

, et al

Intratumoral injection of interferon-a and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy

.

Int J Cancer

2011

;

128

:

105

–

18

.

De Palma

M

,

Mazzieri

R

,

Politi

LS

,

Pucci

F

,

Zonari

E

,

Sitia

G

, et al

Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis

.

Cancer Cell

2008

;

14

:

299

–

311

.

Brody

JD

,

Ai

WZ

,

Czerwinski

DK

,

Torchia

JA

,

Levy

M

,

Advani

RH

, et al

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

.

J Clin Oncol

2010

;

28

:

4324

–

32

.

Garbe

C

,

Peris

K

,

Hauschild

A

,

Saiag

P

,

Middleton

M

,

Spatz

A

, et al

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

.

Eur J Cancer

2010

;

46

:

270

–

83

.

Hodi

FS

,

O'Day

SJ

,

McDermott

DF

,

Weber

RW

,

Sosman

JA

,

Haanen

JB

, et al

Improved survival with ipilimumab in patients with metastatic melanoma

.

N Engl J Med

2010

;

363

:

711

–

23

.

Messing

EM

,

Manola

J

,

Wilding

G

,

Propert

K

,

Fleischmann

J

,

Crawford

ED

, et al

Eastern Cooperative Oncology Group/Intergroup trial

.

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial

.

J Clin Oncol

2003

;

21

:

1214

–

22

.

Pizzocaro

G

,

Piva

L

,

Colavita

M

,

Ferri

S

,

Artusi

R

,

Boracchi

P

, et al

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study

.

J Clin Oncol

2001

;

19

:

425

–

31

.

Motzer

RJ

,

Hutson

TE

,

Tomczak

P

,

Michaelson

MD

,

Bukowski

RM

,

Rixe

O

, et al

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

.

N Engl J Med

2007

;

356

:

115

–

24

.

Quesada

JR

,

Reuben

J

,

Manning

JT

,

Hersh

EM

,

Gutterman

JU

.

Alpha interferon for induction of remission in hairy-cell leukemia

.

N Engl J Med

1984

;

310

:

15

–

8

.

Alfaro

C

,

Suarez

N

,

Gonzalez

A

,

Solano

S

,

Erro

L

,

Dubrot

J

, et al

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

.

Br J Cancer

2009

;

100

:

1111

–

9

.

Kumar

S

.

Multiple myeloma – current issues and controversies

.

Cancer Treat Rev

2010

;

36

[Suppl 2]

:

S3

–

11

.

Zhan

H

,

Spivak

JL

.

The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era

.

Clin Adv Hematol Oncol

2009

;

7

:

334

–

42

.

Levine

RL

,

Wadleigh

M

,

Cools

J

,

Ebert

BL

,

Wernig

G

,

Huntly

BJ

, et al

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

.

Cancer Cell

2005

;

7

:

387

–

97

.

Kiladjian

JJ

,

Cassinat

B

,

Turlure

P

,

Cambier

N

,

Roussel

M

,

Bellucci

S

, et al

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

.

Blood

2006

;

108

:

2037

–

40

.

Talpaz

M

,

Kantarjian

HM

,

McCredie

KB

,

Keating

MJ

,

Trujillo

J

,

Gutterman

J

.

Clinical investigation of human alpha interferon in chronic myelogenous leukemia

.

Blood

1987

;

69

:

1280

–

8

.

Baccarani

M

,

Rosti

G

,

de Vivo

A

,

Bonifazi

F

,

Russo

D

,

Martinelli

G

, et al

Italian Cooperative Study Group on Myeloid Leukemia. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

.

Blood

2002

;

99

:

1527

–

35

.

Guilhot

F

,

Chastang

C

,

Michallet

M

,

Guerci

A

,

Harousseau

JL

,

Maloisel

F

, et al;

French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia

.

N Engl J Med

1997

;

337

:

223

–

9

.

Silver

RT

,

Woolf

SH

,

Hehlmann

R

,

Appelbaum

FR

,

Anderson

J

,

Bennett

C

, et al

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology

.

Blood

1999

;

94

:

1517

–

36

.

O'Brien

SG

,

Guilhot

F

,

Larson

RA

,

Gathmann

I

,

Baccarani

M

,

Cervantes

F

, et al

IRIS Investigators

.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

.

N Engl J Med

2003

;

348

:

994

–

1004

.

Greinwald

JH

Jr,

Burke

DK

,

Bonthius

DJ

,

Bauman

NM

,

Smith

RJ

.

An update on the treatment of hemangiomas in children with interferon alfa-2a

.

Arch Otolaryngol Head Neck Surg

1999

;

125

:

21

–

7

.

Vanni

T

,

Sprinz

E

,

Machado

MW

,

Santana

RdeC

,

Fonseca

BA

,

Schwartsmann

G

.

Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives

.

Cancer Treat Rev

2006

;

32

:

445

–

55

.

©2011 American Association for Cancer Research.

2011